arrow
L

Luca Rapparini

IRCCS Azienda Ospedaliero-Universitaria di Bologna
H指数:7
被引数:169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis

Sacituzumab Govitecan相关的皮肤不良事件:EADV工作组“癌症患者皮肤病学”的国际回顾性研究及药物警戒分析

2026-09-280
PRE
Effectiveness and Safety of Apremilast in Immune Checkpoint Inhibitor-Associated Psoriasis: A Retrospective Multicenter Study From the EADV Task Force “Dermatology for Cancer Patients”

阿普米沙坦在免疫检查点抑制剂相关银屑病中的有效性与安全性:欧洲皮肤病学会联合会“癌症患者皮肤病学”工作组的多中心回顾性研究

2026-09-110
PRE
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study
2026-09-010
PRE
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study

利特昔替尼治疗严重斑秃:一项为期24周、多中心、真实世界研究

2026-03-190
OA
Dermatologic adverse events associated with amivantamab: A multicentre study

与阿曼曲单抗相关的皮肤不良事件:一项多中心研究

2026-02-110
PRE
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results

巴瑞替尼在严重斑秃中的有效性与安全性:48周结果

2025-09-230
PRE
Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients

癌症治疗相关的指甲毒性:EADV肿瘤患者皮肤病学工作组的心得与建议

2025-09-090
PRE